News
-
-
PRESS RELEASE
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
MedMira Inc. announces the receipt of a Canadian patent for a new quantitative test system using Rapid Vertical Flow Technology, enhancing its diagnostic tests. The system offers qualitative and quantitative results in minutes, revolutionizing disease screening and monitoring -
PRESS RELEASE
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
MedMira Inc. provides an update on its submission to Health Canada, extending its intended use to address the increasing need in maternity screening. The company's syphilis component demonstrates promising results, with plans to submit a comprehensive dataset for additional claims approval by February 2024 -
PRESS RELEASE
Corporate Update on Clinical Evaluation of MedMira’s Products
MedMira Inc. provides update on Health Canada review process for maternity screening, highlighting increasing need due to rising syphilis infection rates. Company's syphilis test performance shows promising results for infectious case detection and maternity screening -
PRESS RELEASE
MedMira Reports First Quarter Results FY2024
MedMira Inc. (TSXV:MIR) has reported its financial results for the quarter ended October 31, 2023. The company achieved significant milestones during this period, including receiving US FDA 510(k) clearance for the HIV-2 claim on its Reveal® G4 Rapid HIV 1/2 antibody test. This approval positions MedMira as a key player in the HIV testing market and allows the company to expand its market share and revenue in the United States. -
-
-
-
PRESS RELEASE
Progress Update on Securities
-
PRESS RELEASE
MedMira Reports Third Quarter Results FY2023
